[Press release] HuidaGene Selected for Presidential Symposium at ASGCT 2025 Annual Meeting, Showcasing 13 Abstracts Demonstrating Breakthroughs in Gene Therapy

   2025.04.18  >>

[Press release] HuidaGene at CRISPR MEDiCiNE 2025: A Celebration of Progress, Promise, and Patients

   2025.04.11  >>

[Press release] HuidaGene Announces Broader Adoption of hfCas12Max Through Sublicensing Agreement to Advance Clinical Cell Therapy Programs

   2025.04.09  >>

[Press release] HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies

   2025.04.01  >>

[Press release] HuidaGene Therapeutics to Present at Multiple Key Conferences Highlighting Advances in CRISPR-based Therapies

   2025.03.03  >>

[Press release] European Medicines Agency Issues Positive Opinion on HuidaGene's Triple-Designation HG004 Orphan Designation Application

   2025.01.08  >>

[Press release] HuidaGene Therapeutics Announces Landmark Publication in Nature Neuroscience Highlighting HG204’s Potential as First RNA-editing Therapy for MECP2 Duplication Syndrom

   2024.12.12  >>

[Press release] HuidaGene Therapeutics Initiates M.U.S.C.L.E. Clinical Trial of HG302 for Duchenne Muscular Dystrophy and Completes First Patient Dosed

   2024.12.12  >>